서울대학교 중앙도서관

S-Space 소개

My S-Space

로그인이 필요합니다.

Login

S-Space

Browse

Author

Jump to a point in the index

Or type in a year

Sort by
In order
Results/Page
Authors/record

Showing results 1 to 15 of 15

Issue Date	Title / Author(s) / Citation	File	Altmetrics
2005-06	Predictors of prescription of morphine for severe cancer pain by physicians in Korea Yun, Y. H.; Park, S. M.; Lee, K.; Chang, Y. J.; Heo, D. S.; Kim, S.-Y.; Hong, Y. S.; Huh, B. Y. ANNALS OF ONCOLOGY Vol.16 No.6, pp. 966-971	DOI
2006-03	Antibiotic use during the last days of life in cancer patients Oh, D. Y.; Kim, J. H.; Kim, D. W.; Im, S. A.; Kim, T. Y.; Heo, D. S.; Bang, Y. J.; Kim, N. K. European Journal of Cancer Care, Vol.15 No.1, pp.74-79	DOI
2006-04	Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients Park, Y. H.; Lee, J. J.; Ryu, M. H.; Kim, S. Y.; Kim, D. H.; Do, Y. R.; Lee, K. H.; Oh, S. J.; Kim, Y. K.; Suh, C. W.; Heo, D. S.; RYoo, B. Y.; Kim, J. K.; Song, H. S.; Lee, W. S.; Kim, H. J.; Bang, Y. J.; Yang, S. H.; Sohn, S. K.; Kang, Y. K. Annals of Hematology, Vol.85 No.4, pp.257-262	DOI
2007-12	Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer Kim, D. -W.; Kim, S. -Y.; Kim, H. -K.; Kim, S. -W.; Shin, S. W.; Kim, J. S.; Park, K.; Lee, M. Y.; Heo, D. S. Annals of Oncology, Vol.18 No.12, pp.2009-2014	DOI
2008-01	A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer Kim, Y. J.; Im, S. -A.; Kim, H. G.; Oh, S. Y.; Lee, K. W.; Choi, I. S.; Oh, D. Y.; Lee, S. H.; Kim, J. H.; Kim, D. W.; Kim, T. Y.; Kim, S. W.; Heo, D. S.; Yoon, Y. B.; Bang, Y. J. Annals of Oncology, Vol.19 No.1, pp.99-103	DOI
2008-02	Efficacy of chemotherapy as a first-line treatment in ocular adnexal extranodal marginal zone B-cell lymphoma Song, E. -K.; Kim, S. -Y.; Kim, T. M.; Lee, K. -W.; Yun, T.; Na, I. -I.; Shin, H.; Lee, S. H.; Kim, D. W.; Khwarg, S. I.; Heo, D. S. Annals of Oncology, Vol.19 No.2, pp.242-246	DOI
2008-03	High tumour islet macrophage infiltration correlates with improved patient survival but not with EGFR mutations, gene copy number or protein expression in resected non-small cell lung cancer Kim, D-W; Min, H. S.; Lee, K-H; Kim, Y. J.; Oh, D-Y; Jeon, Y. K.; Lee, S. -H.; Im, S. -A.; Chung, D. H.; Kim, Y. T.; Kim, T. -Y.; Bang, Y. -J.; Sung, S. W.; Kim, J. H.; Heo, D. S. British Journal of Cancer, Vol.98 No.6, pp.1118-1124	DOI
2008-04	Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group Kim, T. M.; Lee, S. Y.; Jeon, Y. K.; Ryoo, B. Y.; Cho, G. J.; Hong, Y. S.; Kim, H. J.; Kim, S. Y.; Kim, C. S.; Kim, S.; Kim, J. S.; Sohn, S. K.; Song, H. H.; Lee, J. L.; Kang, Y. K.; Yim, C. Y.; Lee, W. S.; Yuh, Y. J.; Kim, C. W.; Heo, D. S. Ann Oncol 2008; 19: 1477-1484	DOI
2008-11	Cancer patients' awareness of clinical trials, perceptions on the benefit and willingness to participate: Korean perspectives Kim, J. W.; Kim, S. -J.; Chung, Y. -H.; Kwon, J. -H.; Lee, H. -J.; Chung, Y. -J.; Kim, Y. J.; Oh, Do-Youn; Lee, S. -H.; Kim, D. -W.; Im, S. -A.; Kim, T. -Y.; Heo, D. S.; Bang, Y. -J. British Journal of Cancer, Vol.99 No.10, pp.1593-1599	DOI
2009-01	Effective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone Kim, B. -S.; Kim, D. -W.; Im, S. -A.; Kim, C. W.; Kim, T. -Y.; Yoon, S. -S.; Heo, D. S.; Bang, Y. -J.; Park, S.; Kim, B. K.; Kim, N. K. Annals of Oncology, Vol.20 No.1, pp.121-128	DOI
2009-03	Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival Kim, J. -S.; Kim, M. -A.; Kim, T. M.; Lee, S. -H.; Kim, D. -W.; Im, S. -A.; Kim, T. -Y.; Kim, W. H.; Yang, H. -K.; Heo, D. S.; Bang, Y. -J.; Lee, K. -U.; Choe, K. -J.; Kim, N. K. British Journal of Cancer, Vol.100 No.5, pp.732-738	DOI
2009-08	Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma Koh, Y.; Kim, T. M.; Jeon, Y. K.; Kwon, T. -K.; Hah, J. H.; Lee, S. -H.; Kim, D. -W.; Wu, H. -G.; Rhee, C. -S.; Sung, M. -W.; Kim, C. W.; Kim, K. H.; Heo, D. S. Annals of Oncology, Vol.20 No.8, pp.1414-1419	DOI
2009-10	Increased quantity of tumor-infiltrating FOXP3-positive regulatory T cells is an independent predictor for improved clinical outcome in extranodal NK/T-cell lymphoma Kim, W. Y.; Jeon, Y. K.; Kim, T. M.; Kim, J. E.; Kim, Y. A.; Lee, S. -H.; Kim, D. -W.; Heo, D. S.; Kim, C. -W. Annals of Oncology, Vol.20 No.10, pp.1688-1696	DOI
2013-08	Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study Lee, J. K.; Shin, J. -Y.; Kim, S.; Lee, S.; Park, C.; Kim, J. -Y.; Koh, Y.; Keam, B.; Min, H. S.; Kim, T. M.; Jeon, Y. -K.; Kim, D. -W.; Chung, D. H.; Heo, D. S.; Lee, S. -H.; Kim, J. -I. Annals of Oncology, Vol.24 No.8, pp.2080-2087	DOI
2017-02	Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial Lee, Se-Hoon; Lee, J. -K.; Ahn, M. -J.; Kim, D. -W.; Sun, J. -M.; Keam, B.; Kim, T. M.; Heo, D. S.; Ahn, J. S.; Choi, Y. -L.; Min, H. -S.; Jeon, Y. K.; Park, K. Annals of Oncology, Vol.28 No.2, pp.292-297	DOI

1